Role of Serum Interleukin-6 as a Predictor of Left Ventricular Hypertrophy among Hypertensive Adults
DOI:
https://doi.org/10.53350/pjmhs02026202.5Keywords:
Interleukin-6, hypertension, left ventricular hypertrophy, LVMI, inflammation, cardiovascular remodeling, biomarker.Abstract
Background: Hypertension is one of the biggest health problems in the world and it is closely linked to structural heart complications especially left ventricular hypertrophy (LVH). It has been found that chronic inflammation has become a primary cause of hypertensive end-organ damage, with Interleukin-6 (IL-6) a central mechanistic cause of this pathway. Nonetheless, regional statistics of Punjab and Pakistan in general are few.
Aim: To test the hypothesis that serum IL-6 is a predictor of LVH in hypertensive adult patients and to test the hypothesis that serum IL-6 relates to left ventricular mass index (LVMI).
Methods: The study involved a cross-sectional analytical study in tertiary care hospitals in Punjab, Pakistan, between June 2024 and May 2025. Hypertensive adults aged 30-70 years (n= 70) were enrolled. Clinical analysis, blood pressure, serum IL-6 (ELISA) and echocardiographic analyses of LVMI were conducted. LVH was considered to be LVMI greater than 115 g/m 2 in men and greater than 95 g/m 2 in women. Data analysis was done with independent t-tests, Pearson correlation, and multivariate logistic regression.
Results: LVH was found in 45.7 percent of the participants. The serum IL-6 levels were much higher in the people having LVH than in those with no LVH (12.14 ± 4.52 pg/mL vs. 6.02 ± 2.48 pg/mL; p = 0.001). A positive relationship was found between IL-6 and LVMI (r = 0.61, p < 0.001). Multivariate analysis also ensured that IL-6 was an independent predictor of LVH (AOR 3.74, 95% CI: 1.827.14), when adjusted readings were done by age, BMI, systolic BP and hypertension duration.
Conclusion: IL-6 levels are high predictors of LVH in hypertensive adults and can be a useful biomarker in the initial diagnosis of cardiac remodeling. Combining IL-6 measurement with the regular assessment of hypertension would improve the early risk stratification and clinical decision-making.
References
Tanaka T, Narazaki M, Kishimoto T. Interleukin-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol. 2019;11(10):a038232. doi:10.1101/cshperspect.a038232
Zhang Y, Zhou Y, Chen S, Zhao Y. Serum interleukin-6 levels and target organ damage in essential hypertension. Hypertens Res. 2019;42(6):956-964. doi:10.1038/s41440-018-0184-3
Ghosh A, Ali N, Gupta R. Role of inflammatory cytokines in left ventricular hypertrophy among hypertensive patients. J Hum Hypertens. 2020;34(4):300-307. doi:10.1038/s41371-019-0242-7
Chen W, Wang J, Liu L, YANG D. Association between IL-6 and cardiac hypertrophy in newly diagnosed hypertensive individuals. Clin Exp Hypertens. 2020;42(3):235-241. doi:10.1080/10641963.2019.1633368
WU Z, LI H, LIANG W. Circulating interleukin-6 predicts left ventricular mass progression in hypertension. Cardiovasc Ther. 2020;2020:9037145. doi:10.1155/2020/9037145
PARIKH R, MOHAN V, VASUDEVAN A. High IL-6 levels and subclinical cardiovascular remodeling in South Asian adults with hypertension. J Am Heart Assoc. 2021;10(5):e019582. doi:10.1161/JAHA.120.019582
Kumar S, Sharma R, DEY B. Systemic inflammation and its link to concentric LV hypertrophy in essential hypertension. Clin Cardiol. 2021;44(12):1722-1728. doi:10.1002/clc.23742
Wang Y, LIU X, Zhou H. IL-6 mediated inflammation predicts adverse cardiac remodeling in hypertensive heart disease. Front Cardiovasc Med. 2021;8:734012. doi:10.3389/fcvm.2021.734012
HAN J, LEE S, PARK J. Cytokine-driven pathways of ventricular remodeling: focus on IL-6 and hypertension. Biomolecules. 2021;11(9):1308. doi:10.3390/biom11091308
THOMAS KL, HALL ME, SHARMA A. Interleukin-6 and left ventricular hypertrophy: clinical correlations in hypertensive African and South Asian populations. Am J Hypertens. 2022;35(2):182-191. doi:10.1093/ajh/hpab160
NAQVI S, ZIA S, RASHID H. Association of inflammatory biomarkers with early LV remodeling in hypertensive Pakistani adults. Pak J Med Sci. 2022;38(6):1568-1574. doi:10.12669/pjms.38.6.5215
FERNANDEZ A, RUIZ M, LOPEZ J. IL-6 as a biomarker for cardiovascular risk stratification in hypertension. Int J Cardiol Hypertens. 2022;12:100123. doi:10.1016/j.ijchy.2022.100123
ZHU X, MAO G, LIU H. Longitudinal association between IL-6 and left ventricular mass in hypertensive subjects. ESC Heart Fail. 2022;9(3):1991-1999. doi:10.1002/ehf2.13980
REHMAN SU, KHAN M, SAEED F. Inflammatory cytokines and structural heart changes in uncontrolled hypertension. Cureus. 2023;15(1):e33311. doi:10.7759/cureus.33311
GUO T, ZHANG L, ZHANG Y. IL-6/JAK/STAT signaling as a determinant of cardiac hypertrophy in hypertension. Hypertension. 2023;81(5):1374-1383. doi:10.1161/HYPERTENSIONAHA.122.21002
Imran A, Raza M, ALI F. Serum IL-6 and echocardiographic markers of LV remodeling in South Asian hypertensive patients. BMC Cardiovasc Disord. 2023;23:515. doi:10.1186/s12872-023-03672-7
CHEN J, XIANG Q, ZHANG P. Predictive value of IL-6 in hypertensive target organ damage: a meta-analysis. Clin Cardiol. 2023;46(8):941-950. doi:10.1002/clc.24113
LEE Y, PARK C, KIM H. IL-6 as a prognostic marker of cardiac hypertrophy progression in high-risk hypertensive adults. Sci Rep. 2024;14:8853. doi:10.1038/s41598-024-65892-3
IQBAL M, SIDDIQUI N, HUSSAIN A. Inflammation-driven ventricular remodeling in hypertension: clinical significance of IL-6 in Pakistani adults. J Pak Med Assoc. 2024;74(2):203-210. doi:10.47391/JPMA.8804
Zhang W, LI Q, ZHOU Z. Interleukin-6 as a determinant of adverse cardiac remodeling: insights from a multicenter hypertensive cohort. Eur Heart J Open. 2025;5(1):oeae002. doi:10.1093/ehjopen/oeae002
Downloads
How to Cite
Issue
Section
License
Copyright (c) 2026 JAHANZAIB MALIK, SALEH RASHEED, FAISAL TOHEED
This work is licensed under a Creative Commons Attribution 4.0 International License.
